Abstract
Objective To investigate the clinical significance and interrelation of long-chain non-coding RNA (lcnRNA) HOXA transcript at the distal tip (HOTTIP) and metabotropic glutamate receptor 1 (mGluR1) in pancreatic cancer patients. Methods Pancreatic cancer samples, which were treated in our hospital were collected. The expression levels of HOTTIP and mGlUR1 mRNA were detected by reverse transcriptase-polymerase chain reaction (RT-PCR) in fresh pancreatic cancer tissue, and those of HOTTIP and mGluR1 protein by Western blotting and immunohistochemistry. Moreover, the relationship between the expression of HOTTIP, mGlUR1 and clinicopathological features was analyzed. Results The levels of HOTTIP and mGlUR1 mRNA and protein were significantly up-regulated in pancreatic cancer tissues as compared with normal pancreatic tissue (P=0.000). The expression of HOTTIP protein was positive in 32 samples (68.09%) and mGlUR1 protein was positive in 30 samples (63.83%). The positive rate of HOTTIP and mGlUR1 in adjacent tissues was 31.91% and 36.17%, respectively, and the difference was also statistically significant (P=0.000). The expression of HOTTIP and mGluR1 was correlated with lymph node metastasis, differentiation degree and TNM stage (P=0.000, 0.004, 0.000). The survival time of HOTTIP and mGlUR1 positive patients was significantly shorter than that of negative patients (P=0.029, 0.047). Cox regression multivariate analysis showed that lymph node metastasis, differentiation degree, TNM stage, HOTTIP and mGlUR1 expression were independent prognostic factors for pancreatic cancer (P=0.022, 0.048, 0.026, 0.000, 0.002). In addition, HOTTIP and mGlUR1 expression showed a significant positive correlation in cervical cancer patients (r=0.689, P=0.002). Conclusion The positive expression of HOTTIP and mGlUR1 is associated with the occurrence, progression and prognosis of pancreatic cancer. Key words: Pancreatic cancer; HOXA transcript at the distal tip; Metabotropic glutamate receptor 1; Pathological features; Prognosis
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
